Bruton Tyrosine Kinase Inhibitors Preserve Anti-CD19 Chimeric Antigen Receptor T-Cell Functionality and Reprogram Tumor Micro-Environment in B-Cell Lymphoma

Researchers revealed that Bruton tyrosine kinase inhibitors (BTKIs) preserved T-cell and CART19 functionality under persistent antigen exposure and further demonstrated that BTKI administration was a potential strategy for mitigating cytokine release syndrome after CART19 treatment.